Peptides DB
Research-centric peptide and protocol reference hub

GHRP-6 record · updated 20h ago

Muscle & body compHealing & recoveryGrade A · human clinicalResearch use only
All 18 studiesJump to the evidenceCompare
What is GHRP-6 used for?

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that acts as a growth hormone secretagogue (GHS). It primarily stimulates the release of growth hormone (GH) from the anterior pituitary gland through the activation of the ghrelin receptor (GHS-R). This mechanism is believed to be mediated by the stimulation of the hypothalamus, which subsequently promotes the release of growth hormone-releasing hormone (GHRH) and inhibits somatostatin, thereby enhancing GH secretion.

How it works: Ghrelin receptor agonist

Primarily researched for · Muscle & body compRoute · Subcutaneous injection

Development stage

where GHRP-6 sits between preclinical work and regulatory approval
  1. 1Cleared
    Preclinical
    Animal / in-vitro work
  2. 2Cleared
    Phase 1
    Safety in humans
  3. 3Cleared
    Phase 2
    Efficacy signal
  4. 4Current
    Phase 3
    Confirmatory trials
  5. 5Not reached
    Approved
    Cleared by a regulator

Stage is inferred from the highest trial phase in the indexed corpus and 27 registered trials. It describes the research record, not a recommendation.

Identity
NameGHRP-6
Chain length—
Molecular weight873 Da
FormulaC46H56N12O6
Structure typeNot established
ClassMuscle
Research levelModerate Research
Discovered byCurated master list · 2026

Mass and formula from PubChem CID 4345065. No verified residue count for this compound.

Pharmacology
MechanismGhrelin receptor agonist
RouteSubcutaneous injection
Half-life—
Time to peak—
Duration—
Extraction confidence0.80
Effect profile · 0–5
These seven scores are generated by the Librarian — an autonomous agent running GPT-4o over the indexed studies, trials and label data for this compound. No human assigns them and no community vote moves them. Last recomputed Aug 16, 2026. How this works →
Research stats
Total studies18
Human / animal / cellular6 / 5 / 1
Highest trial phasePhase 3
Years covered2006–2026
Latest study9d ago
Publication history
20062026
Research funding
347,057 NIH projects · $23.4M awarded · through FY2026
Public grants naming this compound. Funding is interest, not evidence.
Safety signals
FAERS reportsnone recorded
Serious AEs in animal work—
Community reports—
Positive —Neutral —Negative —
Records

Study register

18 rows · newest 12 shownOpen in the library →
StudyTypeYearSummary depth
LDH-mediated autophagic full-chain blockade for Multiple Myeloma treatment by targeting circ_0008255/miR-192-5p/ATG2A axis.
FindingNot reported in abstract.
Human2026Full text read0.70
Loss of EGFR activity in skeletal stem/progenitor cells is associated with impaired fracture healing in aged mice.
FindingNot reported in abstract.
Animal2026Full text read0.70
Long-term exploratory evaluation of an acellular biomimetic polyfascicular nerve guidance conduit for peripheral nerve repair in a rhesus macaque model.
Finding94% reduction in PLCL molecular weight at 12 months.
Animal2026Full text read0.80
Areca catechu L. procyanidins alleviate pulmonary fibrosis by suppressing the TGF-β/Smad/ERK cascade: Validation of a traditional herbal medicine.
FindingANP significantly reduced collagen deposition (HYP), p-Smad3/4, and p-ERK levels.
Animal2026Full text read0.70
In vivo antimalarial activity and acute toxicity of organic and aqueous leaf, stem and root extracts of Ajuga integrifolia Buch.-Ham. ex D. Don.
FindingOrganic stem extracts at 500 mg/kg/day suppressed parasite growth by 66.73%.
Animal2026Full text read0.70
Transfer of chloroplast <i>rbcL</i> and <i>atpB</i> genes to nucleus enables partial rescue of photoautotrophic growth of Chlamydomonas.
FindingATPB protein levels reached only 7-10% of the wild-type level.
In vitro2006Full text read0.70
Effects of light intensity on growth and leaf functional trait plasticity of <i>Paris polyphylla var. yunnanensis</i>.
Finding63.54-64.4 g rhizome fresh weight under 40%-60% natural light.
—2026Full text read0.70
The influence of zinc oxide utilization in ruminants: A systematic review and meta-analysis.
FindingSMD = -1.281; 95% CI: -1.818 to -0.743; P < 0.001 for methane production reduction.
review2026Full text read0.80
Reference values for foot morphological characteristics: a cross-sectional study of urban Chinese children aged 9-36 months.
FindingMedian foot length increased from 11.29 cm to 15.07 cm in boys.
Human2026Full text read0.90
GHRELIN IMPAIRS EMBRYO DEVELOPMENT AFTER OVARIAN HYPERSTIMULATION.
FindingDelay in embryo development at GD 3.5 reversed by (D-Lys3)-GHRP-6.
Animal2026Full text read0.70
Phase III Open-Label, Randomized Clinical Trial of Epidermal Growth Factor and Growth Hormone Releasing Hexapeptide in Acute Ischemic Stroke.
FindingmRS at 6 months for severe-stroke patients (NIHSS≥15) treated with EGF+GHRP6 was 2.6 (95%CI: 1.3-3.8) vs Control 4.7 (95%CI: 2.6-6); p=0.03.
Human2026Full text read0.80
Informing policy through evidence: A scoping review of factors that influence enrolment in community-based health insurance in East Africa.
TakeawayThis review highlights the multifaceted determinants of enrolment in community-based health insurance schemes in East Africa, emphasizing the need for a comprehensive approach to enhance participation.
review2026Full text read0.70

What people are saying

anecdotal · not evidence

Unverified first-hand accounts from public forums. These are not studies: nobody checked what was taken, whether it was what the label said, or what else was going on. They count for nothing in the evidence grade above and are shown because a reader searching GHRP-6 will meet them anyway, and meeting them next to a graded evidence base is better than meeting them alone.

Community collection has not run yet, so this is an empty shelf rather than a quiet one — nothing has been read, and no conclusion about how much GHRP-6 is discussed should be drawn from it.